Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective raised by Robert W. Baird from $761.00 to $875.00 in a report issued on Monday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the company. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a report on Thursday, October 1st. Finally, Canaccord Genuity Group lifted their price objective on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $898.97.

Regeneron Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ REGN opened at $930.67 on Monday. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $991.73. The firm has a 50-day moving average price of $800.69 and a 200 day moving average price of $741.11. The stock has a market capitalization of $95.82 billion, a price-to-earnings ratio of 20.38, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the business posted $11.83 earnings per share. The firm’s revenue for the quarter was up 36.3% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 51.64 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 20,789 shares of company stock valued at $18,766,698 in the last quarter. 6.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $5,682,636,000. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Regeneron Pharmaceuticals by 8.5% during the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after acquiring an additional 101,469 shares during the last quarter. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after acquiring an additional 3,742 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $473,872,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.